Gross Profit Margin (Quarterly) Chart

View Gross Profit Margin (Quarterly) for OMER.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Gross Profit Margin (Quarterly) Chart
Start Trial

Historical Gross Profit Margin (Quarterly) Data

View and export this data back to 2009. Start Trial.
Date Value
June 30, 2026 96.50%
March 31, 2026 91.65%
December 31, 2025
September 30, 2025
June 30, 2025
March 31, 2025
December 31, 2024
September 30, 2024
June 30, 2024
March 31, 2024
December 31, 2023
September 30, 2023
June 30, 2023
March 31, 2023
December 31, 2022
September 30, 2022
June 30, 2022
March 31, 2022
December 31, 2021
September 30, 2021
June 30, 2021
March 31, 2021
December 31, 2020
September 30, 2020 96.93%
June 30, 2020 95.87%
Date Value
March 31, 2020 97.16%
December 31, 2019 97.22%
September 30, 2019 97.61%
June 30, 2019 98.20%
March 31, 2019 97.67%
December 31, 2018 98.59%
September 30, 2018 94.34%
June 30, 2018 86.77%
March 31, 2018 80.20%
December 31, 2017 96.61%
September 30, 2017 99.15%
June 30, 2017 99.08%
March 31, 2017 97.79%
December 31, 2016 97.06%
September 30, 2016 96.65%
June 30, 2016 96.73%
March 31, 2016 95.59%
December 31, 2015 93.75%
September 30, 2015 92.39%
June 30, 2015 88.55%
March 31, 2015 82.99%
December 31, 2014 0.00%
September 30, 2014 0.00%
June 30, 2014 0.00%
March 31, 2014 0.00%

Gross Profit Margin Definition

Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.

Read full definition.

Gross Profit Margin (Quarterly) Range, Past 5 Years

View Gross Profit Margin (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Gross Profit Margin (Quarterly) Benchmarks

View Gross Profit Margin (Quarterly) Benchmarks
Start Trial
Eli Lilly & Co. 85.78%
Talphera, Inc. --
Hyperion DeFi, Inc. --
ANI Pharmaceuticals, Inc. 54.97%
Corcept Therapeutics, Inc. 98.41%

Gross Profit Margin (Quarterly) Related Metrics